Medigene Moves Towards Clinic With Lead IO Candidate

Selwyn Ho, CEO of Medigene, discusses the company’s pipeline strategy and upcoming milestones for its immuno-oncology platform.   

T cells attacking cancer cells
T-cells attacking cancer cells • Source: Shutterstock

German biotech Medigene AG is focused on developing T-cell receptor engineered T-cell (TCR-T) therapies for the treatment of solid tumors. After $29.4m was raised in 2022, a further $6.3m this year has provided a small cash boost to fund R&D plans.

The company hopes to transition its in-house lead program, MDG1015, which targets NY-ESO-1 and LAGE-1a, into clinical trials in the...

More from Innovation

More from In Vivo